BioCentury | Apr 11, 2011
Financial News

Calyx Chemicals and Pharmaceuticals Ltd. proposes IPO

...Price: TBD Underwriters: PL Capital Markets; Yes Bank; Punjab National Bank; Link Intime India Note: Calyx...
BioCentury | Apr 19, 2004
Company News

Bayhill names Schwartz CEO

...president, CEO and a director. Schwartz formerly was president and CEO of inflammatory disease company Calyx...
BioCentury | Jan 28, 2002
Finance

U.S. & Canadian IPO candidates

...Business Acorda (U.S.) $39.7M Neurological Achillion (U.S.) $65.0M Infectious diseases Altus (U.S.) $50.0M Chemistry, proteomics Calyx...
BioCentury | Jan 14, 2002
Finance

2002 Financial Markets Preview: Repricing the venture space

...a unifying environment for taking longer on investments," said Mark Schwartz, president and CEO of Calyx Therapeutics Inc....
BioCentury | Dec 10, 2001
Finance

Stocking stuffers

...private equity space was not left out, with some of the big deals highlighted by Calyx...
...one Phase I) in diabetes and rheumatoid arthritis. If the IPO markets firm, look for Calyx...
...If not, the company has some breathing room, as the cash will last into 2003. Calyx...
BioCentury | Dec 10, 2001
Finance

Stocking stuffers

...private equity space was not left out, with some of the big deals highlighted by Calyx...
...one Phase I) in diabetes and rheumatoid arthritis. If the IPO markets firm, look for Calyx...
...If not, the company has some breathing room, as the cash will last into 2003. Calyx...
BioCentury | Dec 10, 2001
Company News

Calyx board of directors update

Calyx Therapeutics Inc., Hayward, Calif. Business: Metabolic, Autoimmune/Inflammation Appointed: Lou Bock, managing director at BA Venture Partners; and Charles Hsu, general partner at Walden International WIR Staff autoimmune Inflammation...
BioCentury | Dec 5, 2001
Financial News

Calyx raises $30 million

...ABS Ventures; and Morgenthaler. The company is developing small molecules for diabetes and inflammatory conditions. Calyx...
BioCentury | May 21, 2001
Company News

Calyx management update

Calyx Therapeutics Inc., Hayward, Calif. Business: Metabolic, Autoimmune/Inflammation Hired: Mark Schwartz as president, CEO and a director, formerly chief commercial officer at Trega BioSciences Inc.; he replaces Somesh Sharma, who will remain CSO WIR Staff...
BioCentury | May 14, 2001
Company News

Calyx appoints Schwartz president and CEO

...Mark Schwartz was named president and CEO of Calyx . Prior to Calyx , he was...
...commercial officer at Trega BioSciences, which was acquired by Lion Bioscience (LEON; NMarkt:LIO) in March. Calyx...
Items per page:
1 - 10 of 16
BioCentury | Apr 11, 2011
Financial News

Calyx Chemicals and Pharmaceuticals Ltd. proposes IPO

...Price: TBD Underwriters: PL Capital Markets; Yes Bank; Punjab National Bank; Link Intime India Note: Calyx...
BioCentury | Apr 19, 2004
Company News

Bayhill names Schwartz CEO

...president, CEO and a director. Schwartz formerly was president and CEO of inflammatory disease company Calyx...
BioCentury | Jan 28, 2002
Finance

U.S. & Canadian IPO candidates

...Business Acorda (U.S.) $39.7M Neurological Achillion (U.S.) $65.0M Infectious diseases Altus (U.S.) $50.0M Chemistry, proteomics Calyx...
BioCentury | Jan 14, 2002
Finance

2002 Financial Markets Preview: Repricing the venture space

...a unifying environment for taking longer on investments," said Mark Schwartz, president and CEO of Calyx Therapeutics Inc....
BioCentury | Dec 10, 2001
Finance

Stocking stuffers

...private equity space was not left out, with some of the big deals highlighted by Calyx...
...one Phase I) in diabetes and rheumatoid arthritis. If the IPO markets firm, look for Calyx...
...If not, the company has some breathing room, as the cash will last into 2003. Calyx...
BioCentury | Dec 10, 2001
Finance

Stocking stuffers

...private equity space was not left out, with some of the big deals highlighted by Calyx...
...one Phase I) in diabetes and rheumatoid arthritis. If the IPO markets firm, look for Calyx...
...If not, the company has some breathing room, as the cash will last into 2003. Calyx...
BioCentury | Dec 10, 2001
Company News

Calyx board of directors update

Calyx Therapeutics Inc., Hayward, Calif. Business: Metabolic, Autoimmune/Inflammation Appointed: Lou Bock, managing director at BA Venture Partners; and Charles Hsu, general partner at Walden International WIR Staff autoimmune Inflammation...
BioCentury | Dec 5, 2001
Financial News

Calyx raises $30 million

...ABS Ventures; and Morgenthaler. The company is developing small molecules for diabetes and inflammatory conditions. Calyx...
BioCentury | May 21, 2001
Company News

Calyx management update

Calyx Therapeutics Inc., Hayward, Calif. Business: Metabolic, Autoimmune/Inflammation Hired: Mark Schwartz as president, CEO and a director, formerly chief commercial officer at Trega BioSciences Inc.; he replaces Somesh Sharma, who will remain CSO WIR Staff...
BioCentury | May 14, 2001
Company News

Calyx appoints Schwartz president and CEO

...Mark Schwartz was named president and CEO of Calyx . Prior to Calyx , he was...
...commercial officer at Trega BioSciences, which was acquired by Lion Bioscience (LEON; NMarkt:LIO) in March. Calyx...
Items per page:
1 - 10 of 16